Consun Pharmaceutical (HKG:1681) launched a share repurchase program of up to HK$200 million under its general buyback mandate, according to a Wednesday Hong Kong bourse filing.
Shares of the firm were down nearly 3% in Thursday's midday trade.
The company said the program will run from May 27 through Dec. 31, with shares to be repurchased on the open market.
Consun intends to fund the repurchases using available cash.